Abstract
Alzheimer’s Disease (AD) presents as a gradual decline in cognitive function, with its characteristic pathology consisting of Amyloid β (Aβ) accumulation and hyperphosphorylated tau. Impaired insulin signalling was recently found in the brain in AD, and shown to increase AD pathology. Similar insulin resistance is found in type 2 diabetes and is currently treated with insulin sensitizers (IS).
Aims and methodThe aim of this literature review was to evaluate whether IS could effectively reduce AD’s characteristic pathology and symptoms in models of AD in transgenic mice. The efficacy of an IS (Metformin, Rosiglitazone or Pioglitazone) at improving each characteristic in transgenic mice was evaluated.
ResultsA variety of cognitive tests and measures of pathology were utilized to assess these outcomes, hindering comparison. Improvements in cognition, learning and Aβ pathology were demonstrated by some papers, and all papers reported a decrease in tau phosphorylation, but no effect on total tau levels.
| Original language | English |
|---|---|
| Article number | 112015 |
| Journal | Behavioural Brain Research |
| Volume | 372 |
| Early online date | 27 Jun 2019 |
| DOIs | |
| Publication status | Published - 17 Oct 2019 |
Keywords
- Insulin sensitizer
- Metformin
- Thiazolidinediones
- Alzheimer’s disease
Access to Document
- Craig_2019_BBR_Insulinsensitizers_AAM
Copyright © 2019 Elsevier B.V. All rights reserved. This work is made available online in accordance with the publisher’s policies. This is the author created, accepted version manuscript following peer review and may differ slightly from the final published version. The final published version of this work is available at https://doi.org/10.1016/j.bbr.2019.112015